%0 Journal Article
%T Stratified Cox Regression Analysis of Survival under CIMAvax<sup>®</sup>EGF Vaccine
%A Carmen Viada Gonzalez
%A Jean-Fran£¿ois Dupuy
%A Martha Fors L¨®pez
%A Patricia Lorenzo Luaces
%A Camilo Rodr¨ªguez Rodr¨ªguez
%A Gisela Gonz¨¢lez Marinello
%A Elia Neninger Vinagera
%A Beatriz Garc¨ªa Verdecia
%A B¨¢rbara Wilkinson Brito
%A Liana Mart¨ªnez P¨¦rez
%A Mayelin Troche de la Concepci¨®n
%A Tania Crombet-Ramos
%J Journal of Cancer Therapy
%P 8-14
%@ 2151-1942
%D 2013
%I Scientific Research Publishing
%R 10.4236/jct.2013.48A002
%X <p class=\"MsoNormal\">
	<b><span lang=\"EN-US\">Background:</span></b><span lang=\"EN-US\"> The
Center of Molecular Immunology (CIM) is a center in <st1:place w:st=\"on\"><st1:country-region w:st=\"on\">Cuba</st1:country-region></st1:place> devoted to the research,
development and manufacturing of biotechnological products. CIMAvax<sup><span style=\"font-size:12.0pt;font-family:\" color:#004080;\"=\"\">?</span></sup>EGF
is a vaccine for the treatment of non-small cell lung cancer patients (NSCL). <b>Purpose: </b>The aim of this work is to
evaluate the effects of some potential prognostic factors on the overall
survival of patients treated with CIMAvax<sup><span style=\"font-size:12.0pt;font-family:\" color:#004080;\"=\"\">?</span></sup>EGF vaccine, based on data
collected in a phase II and a phase III clinical trials. <b>Methods:</b> The stratified Cox regression model is used to evaluate the
effects of these prognostic factors, based on separate analysis for each trial,
and on the combined data from both trials. <b>Results: </b>Patients with Per</span><span lang=\"EN-US\">formance
status 0 or 1, with IV stage of tumor and male under 60 years obtain more
benefit in terms</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">of
overall survival if they receive CIMAvax<sup><span style=\"font-size:12.0pt;font-family:\" color:#004080;\"=\"\">?</span></sup>EGF</span><span lang=\"EN-US\">.</span><span lang=\"EN-US\"> <b>Conclusions:</b> Vaccinated group has a better performance if patients have a perform</span><span lang=\"EN-US\">ance status 0 or 1, stage IV and age
under 60 years. These prognostic factors influence overall survival in a positive
way for those patients that received CIMAvax<sup><span style=\"font-size:12.0pt;font-family:\" color:#004080;\"=\"\">?</span></sup>EGF.</span><span lang=\"EN-US\"><o:p></o:p></span> 
</p>
%K Stratified Cox Regression Model
%K Risk Factor
%K Non-Small Lung Cancer
%K Censored Data
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=35944